4//SEC Filing
Furey John 4
Accession 0001609351-18-000032
CIK 0001609351other
Filed
Apr 18, 8:00 PM ET
Accepted
Apr 19, 4:23 PM ET
Size
13.6 KB
Accession
0001609351-18-000032
Insider Transaction Report
Form 4
Furey John
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2018-04-17$49.74/sh+2,277$113,258→ 2,277 total - Exercise/Conversion
Employee Stock Option (right to buy)
2018-04-17−2,277→ 137,723 totalExercise: $49.74Exp: 2026-11-30→ Common Stock (2,277 underlying) - Sale
Common Stock
2018-04-18$82.53/sh−11,000$907,830→ 0 total - Sale
Common Stock
2018-04-17$82.50/sh−2,277$187,853→ 0 total - Exercise/Conversion
Common Stock
2018-04-18$49.74/sh+11,000$547,140→ 11,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2018-04-18−11,000→ 126,723 totalExercise: $49.74Exp: 2026-11-30→ Common Stock (11,000 underlying)
Footnotes (3)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $82.68, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form.
- [F3]25% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017.
Documents
Issuer
Spark Therapeutics, Inc.
CIK 0001609351
Entity typeother
Related Parties
1- filerCIK 0001691218
Filing Metadata
- Form type
- 4
- Filed
- Apr 18, 8:00 PM ET
- Accepted
- Apr 19, 4:23 PM ET
- Size
- 13.6 KB